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ABSTRACT
This report describes the characterisation of a
mycobacterium involved in a case of septic arth-
ritis in an AIDS patient that was treated success-
fully with specific anti-mycobacterial drugs. The
biochemical and cultural features, and the mycolic
acid pattern as assessed by high-performance
liquid chromatography, were fully compatible
with the isolate being Mycobacterium flavescens.
However, the isolate’s 16S rDNA sequence dif-
fered by five nucleotides from the two known
sequevars of M. flavescens, thus indicating that this
isolate belonged to a new 16S rDNA sequevar.
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Mycobacterium flavescens is a scotochromogenic
mycobacterium, characterised by an intermediate
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growth rate, that was described for the first time
in 1962 following isolation from a drug-treated
tuberculous guinea-pig [1]. Although the isolation
of M. flavescens from human specimens is not
uncommon, only in extremely rare cases has this
organism been considered to be responsible for
disease. The authoritative review by Wayne and
Sramek [2] reported only five human infec-
tions ‘tentatively or confidently attributed to
M. flavescens’, and noted that none of these cases
provided ‘sufficient description of the organism
to permit the identification to be evaluated’. Five
further cases, again with few details of the
identification of the organism, have been reported
subsequently [3–7].
The present report describes a case of septic
arthritis attributed to an organism with the
distinctive phenotypic features of M. flavescens
and a unique nucleotide sequence within the 16S
rRNA gene that closely resembled the sequences
characterising this species. Conventional investi-
gations included all of the biochemical and
cultural tests performed most frequently [8]. The
cell-wall mycolic acids were investigated by high-
performance liquid chromatography (HPLC) ana-
lysis as recommended by the Centers for Disease
Control and Prevention for the UV detection of
mycolic acid following its derivatisation to
bromophenacyl esters [9]. Antimicrobial suscep-
tibilities to ciprofloxacin, clarithromycin, etham-
butol, rifabutin, rifampicin and streptomycin
were investigated by determining the MICs in
liquid radiometric medium following the proce-
dure recommended for organisms belonging to
the Mycobacterium avium complex [10]. The com-
plete sequence of both strands of the 16S rDNA
was determined as described previously [11].
The organism, coded FI-28796, was isolated in
1996 from a 34-year-old haemophilic male, who
had been HIV-seropositive since the age of
22 years and was recognised as an AIDS case
11 years later following the development of oeso-
phageal candidosis. The patient was hospitalised
because of symptoms consistent with acute septic
arthritis (fever, pain, swollen joints). The synovial
fluid yielded by arthrocentesis was yellowish in
colour and dense in appearance, and microscopy
revealed giant-cell phlogosis. The CD4+ lympho-
cyte count was 1 cell ⁄mL and the HIV-1 load was
446 911 copies ⁄mL. Following the isolation of an
acid-fast bacillus from the fluid, empirical treat-
ment with clarithromycin, ciprofloxacin and eth-
ambutol was initiated. MICs for the isolate were as
follows: ciprofloxacin £ 1 mg ⁄mL, clarithromycin
£ 2 mg ⁄mL, ethambutol £ 2 mg ⁄mL, rifabutin
1 mg ⁄mL, rifampicin 2 mg ⁄mL and streptomycin
£ 2 mg ⁄mL, thus confirming that the empirical
treatment was appropriate. Treatment was dis-
continued after 4 months (clarithromycin was
discontinued 1 month earlier), at which time the
articular symptoms had resolved completely;
there has been no relapse to date.
The mycobacterial isolate was identified ini-
tially as M. flavescens by HPLC and cultural
features such as an intermediate growth rate at
25–37C, the scotochromogenic pigmentation of
the smooth colonies, tolerance to NaCl 5% w ⁄v,
and positive tests for nitrate, 68C catalase,
semiquantitative catalase (> 45 mm), Tween-80
hydrolysis and urease. The 16S nucleotide se-
quence (GenBank accession number AJ536296) of
the isolate differed from any others reported so
far. Three species, i.e., Mycobacterium brumae,
Mycobacterium goodii and M. flavescens, shared
Fig. 1. Alignment of 16S rDNA, including the hypervariable region A, from FI-28796, Mycobacterium flavescens,
Mycobacterium brumae and Mycobacterium goodii, commencing with position corresponding to base 118 on the Escherichia
coli 16S rDNA. sqv., sequevar.
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the highest matching score (95% identity) [12]. If
indeterminate nucleotides were considered as
matching, each species had five mismatches in
the hypervariable region A (Fig. 1). Of the three
possibilities, only M. flavescens appeared to be
phenotypically compatible with FI-28796, as the
other species are non-chromogenic and grow
rapidly with completely different HPLC patterns
(Fig. 2). The mismatch of five nucleotides within a
stretch of 150 bases compares with the discrep-
ancy of six bases located in the hypervariable
region A and in the adjacent trait (Fig. 1) that
distinguishes sequevars 1 and 2 of M. flavescens.
Therefore, combined with the excellent match of
the phenotypic features, it seems that FI-28796
represents a third, previously undescribed,
sequevar of the species M. flavescens.
In conclusion, this is the first report in which
the in-depth characterisation of the isolate,
according to recent recommendations [13], is con-
sistent with the involvement in human infection
of an organism belonging, or at least highly
related, to the species M. flavescens. Although
repeated joint bleeding and the patient’s immu-
nosuppression were the predisposing factors for
the arthritis, the systemic (fever) and local (swell-
ing, pain) signs of infection, coupled with
response to specific anti-mycobacterial treatment,
suggests that the isolated organism was the
causative agent of the infection.
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Fig. 2. Representative HPLC patterns of FI-28796, Myco-
bacterium flavescens, Mycobacterium brumae and Mycobacte-
rium goodii. LMMIS, low molecular mass internal standard;
HMMIS, high molecular mass internal standard.
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